Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 3:14:1117076.
doi: 10.3389/fendo.2023.1117076. eCollection 2023.

Circulating biomarkers during progression to type 1 diabetes: A systematic review

Affiliations

Circulating biomarkers during progression to type 1 diabetes: A systematic review

Ekua W Brenu et al. Front Endocrinol (Lausanne). .

Abstract

Aim: Progression to type 1 diabetes (T1D) is defined in stages and clinical disease is preceded by a period of silent autoimmunity. Improved prediction of the risk and rate of progression to T1D is needed to reduce the prevalence of diabetic ketoacidosis at presentation as well as for staging participants for clinical trials. This systematic review evaluates novel circulating biomarkers associated with future progression to T1D.

Methods: PubMed, Ovid, and EBSCO databases were used to identify a comprehensive list of articles. The eligibility criteria included observational studies that evaluated the usefulness of circulating markers in predicting T1D progression in at-risk subjects <20 years old.

Results: Twenty-six studies were identified, seventeen were cohort studies and ten were case control studies. From the 26 studies, 5 found evidence for protein and lipid dysregulation, 11 identified molecular markers while 12 reported on changes in immune parameters during progression to T1D. An increased risk of T1D progression was associated with the presence of altered gene expression, immune markers including regulatory T cell dysfunction and higher short-lived effector CD8+ T cells in progressors.

Discussion: Several circulating biomarkers are dysregulated before T1D diagnosis and may be useful in predicting either the risk or rate of progression to T1D. Further studies are required to validate these biomarkers and assess their predictive accuracy before translation into broader use.

Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier (CRD42020166830).

Keywords: biomarkers; disease progression; immune markers; islet autoimmunity; miRNA; systematic review; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flow chart of selection of studies for the systematic review.
Figure 2
Figure 2
Circulating biomarkers associated with different stages of T1D progression.

References

    1. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect (2020) 10(2):98–115. doi: 10.34172/hpp.2020.18 - DOI - PMC - PubMed
    1. Chobot A, Polanska J, Brandt A, Deja G, Glowinska-Olszewska B, Pilecki O, et al. . Updated 24-year trend of type 1 diabetes incidence in children in Poland reveals a sinusoidal pattern and sustained increase. Diabetes Med (2017) 34(9):1252–8. doi: 10.1111/dme.13345 - DOI - PubMed
    1. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet (2018) 391(10138):2449–62. doi: 10.1016/S0140-6736(18)31320-5 - DOI - PMC - PubMed
    1. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: Abbreviated report of a WHO consultation. Geneva: WHO Guidelines Approved by the Guidelines Review Committee; (2011). - PubMed
    1. Insel R, Dutta S, Hedrick J. Type 1 diabetes: Disease stratification. BioMed Hub (2017) 2(Suppl 1):111–26. doi: 10.1159/000481131 - DOI - PMC - PubMed

Publication types